» Articles » PMID: 35379853

A Targetable 'rogue' Neutrophil-subset, [CD11b+DEspR+] Immunotype, is Associated with Severity and Mortality in Acute Respiratory Distress Syndrome (ARDS) and COVID-19-ARDS

Abstract

Neutrophil-mediated secondary tissue injury underlies acute respiratory distress syndrome (ARDS) and progression to multi-organ-failure (MOF) and death, processes linked to COVID-19-ARDS. This secondary tissue injury arises from dysregulated neutrophils and neutrophil extracellular traps (NETs) intended to kill pathogens, but instead cause cell-injury. Insufficiency of pleiotropic therapeutic approaches delineate the need for inhibitors of dysregulated neutrophil-subset(s) that induce subset-specific apoptosis critical for neutrophil function-shutdown. We hypothesized that neutrophils expressing the pro-survival dual endothelin-1/VEGF-signal peptide receptor, DEspR, are apoptosis-resistant like DEspR+ cancer-cells, hence comprise a consequential pathogenic neutrophil-subset in ARDS and COVID-19-ARDS. Here, we report the significant association of increased peripheral DEspR+CD11b+ neutrophil-counts with severity and mortality in ARDS and COVID-19-ARDS, and intravascular NET-formation, in contrast to DEspR[-] neutrophils. We detect DEspR+ neutrophils and monocytes in lung tissue patients in ARDS and COVID-19-ARDS, and increased neutrophil RNA-levels of DEspR ligands and modulators in COVID-19-ARDS scRNA-seq data-files. Unlike DEspR[-] neutrophils, DEspR+CD11b+ neutrophils exhibit delayed apoptosis, which is blocked by humanized anti-DEspR-IgG4 antibody, hu6g8, in ex vivo assays. Ex vivo live-cell imaging of Rhesus-derived DEspR+CD11b+ neutrophils showed hu6g8 target-engagement, internalization, and induction of apoptosis. Altogether, data identify DEspR+CD11b+ neutrophils as a targetable 'rogue' neutrophil-subset associated with severity and mortality in ARDS and COVID-19-ARDS.

Citing Articles

Circulating neutrophil extracellular trap-forming neutrophils in rheumatoid arthritis exacerbation are majority dual endothelin-1/signal peptide receptor+ subtype.

Cross A, Wright H, Choi J, Edwards S, Ruiz-Opazo N, Herrera V Clin Exp Immunol. 2024; 218(2):163-168.

PMID: 39110036 PMC: 11482496. DOI: 10.1093/cei/uxae072.


The double-edged role of neutrophil heterogeneity in inflammatory diseases and cancers.

Zhou W, Cao X, Xu Q, Qu J, Sun Y MedComm (2020). 2023; 4(4):e325.

PMID: 37492784 PMC: 10363828. DOI: 10.1002/mco2.325.


Predictors of COVID-19 Severity in Elderly Patients Infected by Omicron in China, 18 December 2022-5 February 2023.

Xing Y, Li Y, Feng L, Huo R, Ma X, Dong Y Infect Drug Resist. 2023; 16:4505-4518.

PMID: 37457796 PMC: 10349581. DOI: 10.2147/IDR.S418622.


Circulating neutrophil extracellular trap (NET)-forming 'rogue' neutrophil subset, immunotype [DEspR + CD11b +], mediate multi-organ failure in COVID-19-.

Herrera V, Bosch N, Lok J, Nguyen M, Lenae K, deKay J Transl Med Commun. 2023; 8(1):12.

PMID: 37096233 PMC: 10111078. DOI: 10.1186/s41231-023-00143-x.


Editorial: Phenotypic and functional heterogeneity of neutrophils.

Tamassia N, Jaillon S Front Immunol. 2023; 14:1195605.

PMID: 37081896 PMC: 10111028. DOI: 10.3389/fimmu.2023.1195605.


References
1.
Cugno M, Meroni P, Gualtierotti R, Griffini S, Grovetti E, Torri A . Complement activation in patients with COVID-19: A novel therapeutic target. J Allergy Clin Immunol. 2020; 146(1):215-217. PMC: 7224678. DOI: 10.1016/j.jaci.2020.05.006. View

2.
Grieshaber-Bouyer R, Nigrovic P . Neutrophil Heterogeneity as Therapeutic Opportunity in Immune-Mediated Disease. Front Immunol. 2019; 10:346. PMC: 6409342. DOI: 10.3389/fimmu.2019.00346. View

3.
Zhou X, Gao X, Fan J, Liu Q, Anwar K, Frey R . LPS activation of Toll-like receptor 4 signals CD11b/CD18 expression in neutrophils. Am J Physiol Lung Cell Mol Physiol. 2004; 288(4):L655-62. DOI: 10.1152/ajplung.00327.2004. View

4.
Holter J, Pischke S, de Boer E, Lind A, Jenum S, Holten A . Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020; 117(40):25018-25025. PMC: 7547220. DOI: 10.1073/pnas.2010540117. View

5.
Cho H, Wendelberger B, Gausche-Hill M, Wang H, Hansen M, Bosson N . ICU-free days as a more sensitive primary outcome for clinical trials in critically ill pediatric patients. J Am Coll Emerg Physicians Open. 2021; 2(4):e12479. PMC: 8262607. DOI: 10.1002/emp2.12479. View